Amgen Inc.

Lisa D Julian

Daqing Sun

Xuelei Yan

Jay Patrick Powers

Yosup Rew

Michael R Degraffenreid

Dustin L McMinn

Felix Gonzalez Lopez De Turiso

Xiao He

Julio Cesar Medina

Frank Kayser

Brian M Fox

Zhulun Wang

Michael D Bartberger

Hilary Plake Beck

Steven H Olson

Jacob A Kaizerman

Philip M Roveto

Julio C Medina

Dustin Mcminn

Jacob Kaizerman

Michael Degraffenreid

The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer

Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R, R, R, R, R, R, R, R, and n are as defined herein.

Benzamide derivatives and uses related thereto

The present invention provides tricyclic compounds according to formula (I): (I) where R, R, R, W, X, Y, Z, m, n, and p are as defined in the description; as well as pharmaceutical compositions comprising the same, methods of use of the compounds and compositions of the invention for the treatment of conditions associated with hydroxysteroid dehydrogenases (e.g., 11-HSD1), and the use of the compounds of the invention in the preparation of medicaments for the treatment of hydroxysteroid dehydrogenase-associated conditions. 

Tricyclic inhibitors of hydroxysteroid dehydrogenases

Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R, R, R, R, R, R, R, R, R, R, R, and Rare defined as provided herein.

Benzamide derivatives of formula I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R, R, R, R, R, R, R, R, R, R, R, and Rare defined as provided herein.

Growing community of inventors

Frisco, CO, United States of America

Lisa D Julian